Oftebro H, Björkhem I, Størmer F C, Pedersen J I
J Lipid Res. 1981 May;22(4):632-40.
Oxidation of the side chain of 5 beta-cholestane-3 alpha, 7 alpha-diol, 7 alpha-hydroxy-4-cholesten-3-one, and 5-cholestene-3 beta, 7 alpha-diol has been studied in subcellular fractions of liver from a patient with cerebrotendinous xanthomatosis (CTX) and a control subject. All intermediates were efficiently 26-hydroxylated and further converted to the corresponding 26-carboxylated derivatives by the mitochondrial fraction of normal human liver. No such conversion was observed with the mitochondria from the liver of the CTX patient and the control subject. 12 alpha-Hydroxylation of the patient and the control subject. 12 alpha-Hydroxylation of the substrates was very efficient with the microsomal fractions from both subjects. Bases on these and previous findings (Oftebro, H., I. Björkhem, S. Skrede, A. Schreiner, and J. I. Pedersen. 1980. J. Clin. Invest. 65: 1481-1430), it i concluded that the metabolic defect in CTX is a complete lack of mitochondrial C27-steroid 26-hydroxylase. In CTX the precursors of chenodeoxycholic acid are first attacked by the microsomal 12 alpha-hydroxylase and subsequently by the microsomal 25-hydroxylase as an alternate route to cholic acid formation. This explains the increased ratio of cholic acid to chenodeoxycholic acid observed in the bile of these patients. In the normal liver the formation of both cholic acid and chenodeoxycholic acid involves a mitochondrial 26-hydroxylation.
在一名患有脑腱性黄瘤病(CTX)的患者和一名对照受试者的肝脏亚细胞组分中,对5β-胆甾烷-3α,7α-二醇、7α-羟基-4-胆甾烯-3-酮和5-胆甾烯-3β,7α-二醇的侧链氧化进行了研究。所有中间体都被正常人肝脏的线粒体组分有效地26-羟基化,并进一步转化为相应的26-羧化衍生物。在CTX患者和对照受试者的肝脏线粒体中未观察到这种转化。患者和对照受试者的底物12α-羟基化在来自两个受试者的微粒体组分中非常有效。基于这些以及先前的发现(奥夫特布罗,H.,I.比约克姆,S.斯克雷德,A.施赖纳,和J.I.佩德森。1980年。《临床研究杂志》65:1481-1430),得出结论,CTX中的代谢缺陷是线粒体C27-类固醇26-羟化酶完全缺乏。在CTX中,鹅去氧胆酸的前体首先被微粒体12α-羟化酶攻击,随后被微粒体25-羟化酶攻击,作为形成胆酸的替代途径。这解释了在这些患者胆汁中观察到的胆酸与鹅去氧胆酸比例增加的现象。在正常肝脏中,胆酸和鹅去氧胆酸的形成都涉及线粒体26-羟基化。